Mavacamten is an approved cardiac myosin inhibitor for the treatment of symptomatic hypertrophic obstructive cardiomyopathy in adults.
Answers are grounded in this paper and cite their sources.
Mavacamten approved for symptomatic obstructive HCM; leaves open long-term outcomes and optimal patient selection.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Marek Lapka (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: